查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969847

2026-2034年全球短肠症候群市场规模、份额、趋势和成长分析报告

Global Short Bowel Syndrome Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 112 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年，短肠症候群市场规模将从 2025 年的 19.2 亿美元达到 40 亿美元，2026 年至 2034 年的复合年增长率为 8.49%。

全球短肠症候群(SBS) 市场正稳定成长，主要受胃肠外科手术量增加以及克隆氏症和其他肠道疾病病例上升的推动。短肠症候群(SBS) 通常需要长期营养支持，包括肠外营养和特殊药物治疗。医疗专业人员对该疾病认识的提高以及诊断技术的进步，使得患者能够及时接受治疗。此外，生物疗法和肠道復健计画的进展也对市场成长产生了积极影响。

推动该市场发展的主要因素包括医疗保健支出不断增长、标靶治疗研发管线实力雄厚以及政府对罕见疾病的支持政策。製药公司正投资研发能够改善营养吸收并减少对肠外营养依赖的创新药物。医院基础设施的改善和专科治疗中心的普及也支撑了市场需求。已开发地区的患者支持计划和报销政策进一步加速了治疗方案的推广应用。

未来，先进的再生医学和新型荷尔蒙疗法有望推动市场发展。肠道适应疗法和基于微生物组的解决方案的研究可能带来新的成长机会。在新兴经济体，随着医疗保健体系的扩展，治疗的可近性有望得到改善。总体而言，持续的临床研究和以患者为中心的创新将塑造短肠症候群市场的长期发展。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球短肠症候群市场：按类型划分

  • 市场分析、洞察与预测
  • GLP-2
  • 生长激素
  • 麸酰胺酸

第五章：全球短肠症候群市场：依分销管道划分

  • 市场分析、洞察与预测
  • 医院药房
  • 线上和线下药局

第六章：全球短肠症候群市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • OxThera
    • Zealand Pharma
    • Ironwood Pharmaceuticals
    • Hanmi Pharm Co. Ltd
    • Jaguar Health
    • Merck KGaA
    • EnteraBio Ltd
    • NestlAfA（C）
    • Salix Pharmaceuticals
简介目录
Product Code: VMR112110467

The Short Bowel Syndrome Market size is expected to reach USD 4.00 Billion in 2034 from USD 1.92 Billion (2025) growing at a CAGR of 8.49% during 2026-2034.

The Global Short Bowel Syndrome Market is growing steadily due to the rising number of gastrointestinal surgeries and increasing cases of Crohn's disease and intestinal disorders. Short bowel syndrome (SBS) often requires long-term nutritional support, including parenteral nutrition and specialized drug therapies. Growing awareness among healthcare professionals and improved diagnosis are helping patients receive timely treatment. In addition, advancements in biologic therapies and intestinal rehabilitation programs are positively influencing market growth.

The main drivers of this market include increasing healthcare spending, a strong pipeline of targeted therapies, and supportive government policies for rare diseases. Pharmaceutical companies are investing in innovative drugs that improve nutrient absorption and reduce dependency on parenteral nutrition. Improved hospital infrastructure and access to specialized care centers are also supporting demand. Patient support programs and reimbursement policies in developed regions further boost treatment adoption.

In the future, the market is expected to benefit from advanced regenerative medicine and novel hormone-based treatments. Research in gut adaptation therapies and microbiome-based solutions may open new growth opportunities. Emerging economies are likely to see improved access to treatment as healthcare systems expand. Overall, continuous clinical research and patient-focused innovations will shape the long-term development of the Short Bowel Syndrome Market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • GLP-2
  • Growth Hormone
  • Glutamine

By Distribution Channel

  • Hospital Pharmacies
  • Online & Retail Pharmacies

COMPANIES PROFILED

  • Takeda Pharmaceutical Company Limited, , OxThera, Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharm Co Ltd, Jaguar Health, Merck KGaA, EnteraBio Ltd, Nestl, Salix Pharmaceuticals
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SHORT BOWEL SYNDROME MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. GLP-2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Growth Hormone Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Glutamine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SHORT BOWEL SYNDROME MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Distribution Channel
  • 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Online & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SHORT BOWEL SYNDROME MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By Distribution Channel
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By Distribution Channel
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By Distribution Channel
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By Distribution Channel
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By Distribution Channel
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SHORT BOWEL SYNDROME INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 OxThera
    • 8.2.2 Zealand Pharma
    • 8.2.3 Ironwood Pharmaceuticals
    • 8.2.4 Hanmi Pharm Co. Ltd
    • 8.2.5 Jaguar Health
    • 8.2.6 Merck KGaA
    • 8.2.7 EnteraBio Ltd
    • 8.2.8 NestlAfA(C)
    • 8.2.9 Salix Pharmaceuticals